Isotechnika Pharma Inc IPHAF

RE: Analysts..........teevee

[stockman6]

"...leaving new transplant patients with little prospect of finding a donar kidney.." I'm pretty sure they could get one at a donar store? Not sure what they would do with it though........ Cyclosporin is used for severe forms of psoriasis. It's been limited to cases where other treatments don't work, largely due to the toxic side effects. If ISAtx247 continues to show increased effectiveness and decreased toxicity, it should not only replace cyclosporin use, but become a more popular treatment in general. You are also overstating the danger of using such a drug, you've insinuated previously also that this is a "dangerous drug", and it's incorrect. Any patient without an already comprimised immune system is a candidate. I agree with your assessment of the potential for kidney transplant recipients. The improved toxicity profile, or therapuetic window, illustrated so far with ISAtx247 is critical, and the very basis for the great potential of the drug, which is why Roche signed the largest deal in Canadian history. I'm glad you finally grasped the concept that ISAtx247 has increased potency AND decreased toxicity. Just curious, did you check up on my research that the "large, well funded" biotechs are currently trading at around 2.6x cash on hand, as oppossed to the 1x that you had incorrectly stated? You also never got back to me yet whether you want be to correct the other six false statements and innuendos in your "Ugly Chart" post. Let me know, I feel bad that you are uneducated, especially when, in my estimations, you lost badly on this stock in the last two years, with ill-timed trades and shorts.......